| |
Number
|
VCAM-1 (pg/ml)
|
ICAM-1 (pg/ml)
|
ELAM-1 (pg/ml)
|
|---|
|
Sex
| | | | |
|
Female
|
64
|
750 (391–2073)
|
356 (135–993)
|
58 (12–144)
|
|
Male
|
10
|
698 (463–1814)
|
480 (235–805)
|
60 (38–149)
|
|
Race
| | | | |
|
Caucasian
|
68
|
750 (391–2073)
|
366 (135–993)
|
61 (12–149)
|
|
Asian
|
6
|
572 (463–971)
|
352 (235–699)
|
49 (35–82)
|
|
Diabetes
| | | | |
|
Yes
|
5
|
674 (554–1338)
|
376 (235–455)
|
55 (52–129)
|
|
No
|
69
|
749 (391–2073)
|
365 (135–993)
|
59 (12–149)
|
|
COX-2 inhibitor use
| | | | |
|
Yes
|
20
|
689 (475–2073)
|
371 (145–749)
|
79 (25–129)
|
|
No
|
54
|
750 (391–2001)
|
363 (135–993)
|
55 (12–149)
|
|
Traditional NSAID use
| | | | |
|
Yes
|
19
|
766 (493–2001)
|
366 (135–993)
|
68 (16–149)
|
|
No
|
55
|
703 (391–2073)
|
365 (145–761)
|
55 (12–129)
|
|
Aspirin use
| | | | |
|
Yes
|
6
|
719 (463–2073)
|
346 (219–595)
|
40 (23–94)
|
|
No
|
68
|
747 (391–2001)
|
366 (135–993)
|
62 (12–149)
|
|
Oestrogen use
| | | | |
|
Yes
|
24
|
673 (445–2001)
|
311 (181–993)
|
53 (12–83)
|
|
No
|
50
|
786 (391–2073)
|
389 (135–805)
|
64 (20–149)
|
|
DMARD use
| | | | |
|
Yes
|
56
|
726 (391–2073)
|
368 (145–805)
|
56 (12–149)
|
|
No
|
18
|
816 (567–2001)
|
358 (135–993)
|
64 (34–115)
|
|
Prednisone use
| | | | |
|
Yes
|
11
|
930 (391–2073)
|
455 (181–761)
|
94 (23–129)
|
|
No
|
63
|
724 (445–2001)
|
361 (135–993)
|
55 (12–149)
|
|
Antihypertensive agent use
| | | | |
|
Yes
|
23
|
744 (569–2073)
|
414 (219–805)
|
66 (16–149)
|
|
No
|
51
|
758 (391–2001)
|
350 (135–993)
|
54 (12–137)
|
- Results for biomarkers are expressed as median (range). Data were analyzed using the Mann–Whitney U test. No comparisons were significant at P ≤ 0.01. COX-2, cyclooxygenase-2; DMARD, disease-modifying antirheumatic drug; ELAM, endothelial leukocyte adhesion molecule; ICAM, intercellular adhesion molecule; NSAID, nonsteroidal anti-inflammatory drug; VCAM, vascular adhesion molecule.
